Lilly Posts Solid Breast Cancer Data, but Pfizer’s Leading Position With Ibrance Remains Intact
Eli Lilly reported strong phase 3 data (Monarch 2) for its CDK4/6 drug abemaciclib in breast cancer, but we continue to believe Pfizer’s Ibrance will dominate the class because of Pfizer’s first-mover advantage and limited differentiating efficacy data from Lilly’s abemaciclib as well as Novartis’ Kisqali. While we see each of these companies as moderately undervalued, Pfizer has the most upside potential, and we continue to believe that Pfizer’s positioning with Ibrance is secure and that Pfize...Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. The company's human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. The company's diabetes and other endocrinology products include: Baqsimi? and Basaglar?. The company's immunology products include: Olumiant? and Taltz?. The company's neuroscience products include: Cymbalta? and Emgality?. The company's oncology products include: Alimta?, Cyramza?, Erbitux? and Verzenio?. The company's other products include: Cialis?.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.